NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

Saturday, April 23, 2022

7:30am – 4:00pm

Earn up to 6.75 AMA PRA Category 1 Credits,™ Continuing Nursing Education (CNEG), and MOC accreditation

 REGISTER HERE

Location

Lexington Marriott City Center
121 W Vine St.
Lexington, KY 40507

Providers

Jointly Provided by the University of Kentucky and the North American Neuroendocrine Tumor Society

Course Director

Lowell Anthony, MD, University of Kentucky

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time-consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
• Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
• Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
• Recognize the clinical features associated with carcinoid syndrome
• Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
• Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

• • B. Mark Evers, MD, FACS, Professor of Surgery and Markey Cancer Center Director, University of Kentucky
    Lowell B. Anthony, MD, FACP, Professor of Medicine, Co-Director of the Radiopharmaceutical Therapy Program,University of Kentucky

• • Epidemiology of NETs
    Simron Singh, MD, MPH, FRCPC, Medical Oncologist, Affiliate Scientist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • Natural History and Clinical Features
    Lowell B. Anthony, MD, FACP, Professor of Medicine, Co-Director of the Radiopharmaceutical Therapy Program, University of Kentucky
  • Imaging for Diagnosis and Disease Surveillance
    Riham El-Khouli, MD, PhD, Associate Professor of Radiology, Director of Theranostics, University of Kentucky

• • Surgical Principles for Early Stage NETs
    Alexandra Gangi, MD, Director of the Gastrointestinal Tumor Program and Cancer Regional Therapies Program, Cedars Sinai Medical Center
  • Management of Metastatic NETs: Role of Debulking Surgery
    James Howe, MD, Professor of Surgery-Surgical Oncology and Endocrine Surgery, University of Iowa, Roy J. and Lucille A. Carver College of Medicine
  • Surgical Management of Pheochromocytomas, Paragangliomas and Medullary Thyroid Cancer
    Cortney Lee, MD FACS, Associate Professor, Endocrine Surgery, University of Kentucky
  • Case Presentation and Panel Moderation: Q/A (all above)
    Jaydira Del Rivero, MD PhD, Physician Scientist in the Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health

• • Charles Kunos, MD, PhD, Professor of Radiation Medicine, Medical Director of Clinical and Investigational Radiotherapeutics, Co-Director of the Radiopharmaceutical Therapy Program, University of Kentucky

• • Aman Chauhan, MD, Assistant Professor of Medicine, Director of NET Theranostics, University of Kentucky

• • Functional NETS, Complications and Hormonal Management
    Thorvardur (Thor) R. Halfdanarson, MD, Professor of Oncology, Associate Professor of Medicine, Mayo Clinic, Rochester, MN
  • Carcinoid Heart Disease: It’s Management and Future Direction
    Heloisa Soares, MD, PhD, Associate Professor, Huntsman Cancer Institute (HCI), University of Utah
  • FDA Approved Therapies for NETs
    Robert Ramirez, DO, Associate Professor of Medicine, Vanderbilt University

• • Hepatic Transarterial Therapies: What the Interventional Oncologic Radiologist Can Offer
    Sarah B. White, MD, MS, FSIR, FCIRSE, Professor of Radiology and Surgical Oncology, Vice-Chair, Radiology Research, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital
  • Case Presentations
    Gaby E. Gabriel, MD, Associate Professor of Radiology & Surgery, Program Director Interventional Radiology residency, University of Kentucky

• • Elise C. Kohn, MD, Head of Neuroendocrine Tumor and Gynecological Cancer Therapeutics, National Cancer Institute

• • Surgical Management of Bronchial Carcinoids
    Shari Meyerson, MD, MEd, Chief, Section of Thoracic Surgery, Director, Thoracic Surgery Training Program, University of Kentucky
  • Medical Management of Thoracic NETs
    Satya Nanu Das, MD, MSCI, Assistant Professor of Medicine, Vanderbilt University
  • Recent Advances in Molecular Characterization of NETs
    Jill Kolesar, PharmD, Professor of Pharmacy, Director, Early Phase Clinical Trials Center, Co-Director, Molecular Tumor Board, University of Kentucky

• • Aman Chauhan, MD, Assistant Professor of Medicine, Director of NET Theranostics, University of Kentucky

• • Lowell B. Anthony, MD, FACP, Professor of Medicine, Co-Director of the Radiopharmaceutical Therapy Program, University of Kentucky

 Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.75 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.75 hours of continuing nursing education credit.

 

In-person registration is available onsite the day of the program and will be accommodated on a space-available basis. Online registration is open until Wednesday, April 20, 2022, 12pm EST

Registration fee:

NANETS Member

$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

 REGISTER HERE  

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before April 15, 2022. On or after April 16, 2022, no refund will be made.

The University of Kentucky and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.